Article Text

other Versions

PDF
Inhibition of experimental corneal neovascularization by Bevacizumab(AVASTIN)
  1. Roberta Manzano (roberta.manzano{at}gmail.com),
  2. Gholam Peyman (gpeyman1{at}yahoo.com),
  3. Palwasha Khan (palwasha_md{at}hotmail.com),
  4. Petros Carvounis (carvounis{at}yahoo.com),
  5. Muhamet Kivilcim (muhamet_kivilcim{at}yahoo.com),
  6. Min Ren (renmin100{at}yahoo.com),
  7. Jonathan Lake (jonathanlake{at}gmail.com),
  8. Patricia Chevez-Barrios (pchevez-barrios{at}tmh.tmc.edu)
  1. Tulane University Health Sciences Center, United States
  2. University of Arizona, United States
  3. Tulane University Health Sciences Center, United States
  4. Cullen Eye Institute, Baylor College of Medicine, United States
  5. University of Arizona, United States
  6. Tulane University Health Sciences Center, United States
  7. Departamento de Oftalmologia, Santa Casa de Misericórdia de São Paulo, Brazil, Brazil
  8. Cullen Eye Institute, Baylor College of Medicine, United States

    Abstract

    Purpose: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularization in rats.

    Materials and Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterization on the corneas of 16 eyes from 16 male Long-Evans (LE) rats. For the following 7 days, the 10 eyes in the treatment group received twice daily instillation of Bevacizumab 4mg/ml drops while the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.

    Results: In the Bevacizumab treated eyes, neovascularization covered, on average, 38.2 ±15.5% (mean ± standard deviation[SD]) of the corneal surface compared with 63.5 ± 5.0% (mean ± SD) in the control group (p<0.02, Mann-Whitney U test).

    Conclusion: Topically administered Bevacizumab (Avastin) at a concentration of 4mg/ml limits corneal neovascularization following chemical injury in the male Long-Evans rat model.

    • Bevacizumab
    • angiogenesis
    • avastin
    • cornea
    • neovascularization

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • BJO at a glance
      Creig Hoyt